|
1) Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol. 1999; 10: 1053-8
|
|
|
|
|
2) Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardio-vascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle？ Clin J Am Soc Nephrol. 2008; 3: 505-21
|
|
|
|
|
3) Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict develo-pment of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Micro-albuminuria (IRMA 2) study. Scand J Clin Lab Invest. 2008; 68: 731-8
|
|
|
|
|
|
4) Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16: 2456-61
|
|
|
|
|
|
5) Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001; 103: 1869-74
|
|
|
|
|
|
6) Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: Role of ADMA for retarding renal disease progression. J Nephrol. 2010; 23: 377-86
|
|
|
|
|
|
7) Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005; 97: e53-9
|
|
|
|
|
|
8) Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethy-larginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001; 358: 2113-7
|
|
|
|
|
|
9) Ravani P, Tripepi G, Malberti F, et al. Asym-metrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005; 16: 2449-55
|
|
|
|
|
|
10) Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009; 119: 1592-600
|
|
|
|
|
|
11) Yamagata K, Daitoku H, Fukamizu A. Regulation of cellular functions by arginine methylation. Seikagaku. 2009; 81: 688-99
|
|
|
|
|
12) Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deminases. Biochem J. 1999; 343: 209-14
|
|
|
|
|
|
13) Hu X, Atzler D, Xu X, et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol. 2011; 31: 1540-6
|
|
|
|
|
|
14) Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethyl-arginine dimethylaminohydrolase. Circulation. 2002; 106: 987-92
|
|
|
|
|
|
15) Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2176-83
|
|
|
|
|
|
16) Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res. 2005; 28: 181-9
|
|
|
|
|
|
17) Böger R, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000; 87: 99-105
|
|
|
|
|
|
18) Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflam-mation. J Am Soc Nephrol. 2009; 20: 2546-55
|
|
|
|
|
|
19) Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141-6
|
|
|
|
|
|
20) Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002; 13: 490-6
|
|
|
|
|
|
21) Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002; 62: 339-45
|
|
|
|
|
|
22) Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethyl-arginine. Am J Kidney Dis. 2006; 47: 42-50
|
|
|
|
|
|
23) Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1115-20
|
|
|
|
|
|
24) Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004; 27: 765-9
|
|
|
|
|
|
25) Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol. 2007; 49: 1099-105
|
|
|
|
|
|
26) Jacobi J, Sydow K, von Degenfeld G, et al. Over-expression of dimethylarginine dimethyl-aminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angio-genesis. Circulation. 2005; 111: 1431-8
|
|
|
|
|
|
27) Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005; 46: 1693-701
|
|
|
|
|
|
28) Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006; 70: 781-7
|
|
|
|
|
|
29) Sharma M, Zhou Z, Miura H, et al. ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol Renal Physiol. 2009; 296: F1386-95
|
|
|
|
|
|
30) Nangaku M. Chronic hypoxia and tubulo-interstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17-25
|
|
|
|
|
|
31) Kielstein JT, Simmel S, Bode-Böger SM, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res. 2004; 27: 143-7
|
|
|
|
|
|
32) Kang DH, Nakagawa T, Feng L, et al. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol. 2002; 161: 239-48
|
|
|
|
|
|
33) Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol. 2007; 18: 1525-33
|
|
|
|
|
|
34) Shibata R, Ueda S, Yamagishi S, et al. In-volvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant. 2009; 24: 1162-9
|
|
|
|
|
|
35) Fujimi-Hayashida A, Ueda S, Yamagishi S, et al. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol. 2011; 33: 1-6
|
|
|
|
|
|
36) Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008; 31: 747-52
|
|
|
|
|
|
37) Hanai K, Babazono T, Nyumura I, et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant. 2009; 24: 1884-8
|
|
|
|
|